October 2016

New Product - Esmya

Esmya (ulipristal acetate) is an orally active synthetic selective progesterone receptor modulator that acts via high‑affinity (nanomolar) binding to the human progesterone receptor. Ulipristal acetate exerts a direct action on fibroids reducing their size through inhibition of cell proliferation and induction of apoptosis. Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. Esmya is contraindicated in: pregnancy and breastfeeding; genital bleeding of unknown aetiology or for reasons other than uterine fibroids; and in uterine, cervical, ovarian or breast cancer. Esmya is available as a 5 mg tablet in blister pack of 28’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629